For CDMOs, staying ahead of the curve means investing not just in capacity, but in capabilities that match where molecules, delivery formats and supply-chain expectations are heading.
Over the next decade, the partners that will matter most to sponsors are likely to be those that combine scalable sterile manufacturing, device integration and global reach with a coherent, long-term investment strategy rather than a series of opportunistic site additions.
Why CDMO investment strategy matters
Over the past decade, pharma and biotech companies have outsourced a rising share of development and manufacturing, particularly for complex injectables and biologics, making CDMOs critical nodes in the global drug supply chain. Some analysts place the global sterile injectables CDMO market at around USD 37 billion in the mid‑2020s, with projections to exceed USD 80 billion by the early 2030s at double‑digit compound annual growth rates (CAGR). Within that, prefilled syringes and other advanced delivery formats are a major driver: one forecast places the prefilled syringes market at around USD 18 billion by 2030/2031, expanding at high single to low double‑digit CAGR as biologics and home‑based care models expand. For CDMOs, this demand is forcing a shift away from incremental debottlenecking toward multi‑year, multi‑site capital plans that can support high‑value, high‑risk therapies at scale.
At the same time, supply-chain resilience has moved from a background concern to a board-level issue after pandemic-era disruptions, geopolitical tensions and increasing regulatory scrutiny around sourcing and quality. Sponsors now expect their CDMO partners not only to provide capacity, but also to offer geographic diversification, redundancy and digital transparency across networks of sites. That environment rewards CDMOs that invest ahead of demand in a disciplined way, aligned to therapeutic and modality trends rather than scattershot expansion.
Strategic themes shaping CDMO investment
Three investment themes now dominate boardroom discussions at leading CDMOs: sterile injectables and biologics, advanced drug-device combination products, and integrated, end-to-end service models.
First, sterile injectables and biologics have become the growth engine of outsourced development and manufacturing, driven by monoclonal antibodies, complex biologics, oligonucleotides, peptides, mRNA and increasingly potent oncology agents. Building suitable capacity is capital-intensive, requiring isolator-based aseptic lines, large-scale lyophilization, containment for highly potent compounds and co-located development laboratories to de-risk late-stage scale-up. Second, advanced drug-device combination products such as prefilled syringes, cartridges, autoinjectors and pens are expanding rapidly as self-administration and patient-centric care models evolve, increasing demand for CDMOs that can manage both drug product and device assembly at commercial scale. Third, sponsors are increasingly seeking end-to-end partnerships in which a single CDMO can support the path from early formulation through clinical manufacturing, combination-product assembly, cold-chain logistics and commercial launch.
These trends are evident in the way investment is flowing: analysts describe the prefilled‑syringe sterile injectables CDMO segment alone as a roughly USD 1.7 billion market in the mid‑2020s, growing at close to 10% annually, with a strong emphasis on large‑scale, automated, isolator‑based operations. Across the industry, the likely winners will be the CDMOs that do not simply add lines, but build networks of facilities that combine scale, flexibility, modality breadth and geographic reach, while embedding strong quality systems and digital connectivity.
A case example: building a sterile injectables network
PCI Pharma Services’ recent investment program offers one example of how a global CDMO is responding to these forces through a coordinated, multi-year strategy. Central to this is a more than USD 1 billion investment plan, supported by backing from its investors focused on expanding sterile fill-finish and advanced drug delivery capabilities across the United States and Europe. Rather than centring on a single project, the strategy spans development centres, aseptic manufacturing, device assembly and packaging, and expanded storage and distribution to support an end-to-end offering for complex injectables.
One cornerstone of this plan was the acquisition of Ajinomoto Althea in San Diego, a US-based sterile fill-finish CDMO, completed as part of PCI’s broader investment strategy. The assets are integrated with PCI’s existing sterile operations to create a large-scale manufacturing hub in San Diego, with aseptic capacity for prefilled syringes and cartridges and strengths in oligonucleotide and peptide manufacturing. More broadly, this reflects a wider pattern in the CDMO market, where targeted acquisitions are being used to add technically differentiated capabilities in sterile injectables, high-potent handling and emerging modalities rather than simply increasing undifferentiated volume.
Scaling sterile fill-finish through targeted capital
Beyond acquisitions, PCI has also invested in large-scale sterile fill-finish and lyophilization capacity within its existing network, particularly in Bedford. That expansion brings online commercial-scale, Annex 1-compliant isolator-based sterile manufacturing and lyophilization designed to support high-volume vial filling and complex injectable programs. In parallel, Pharmaceutical Development Centers of Excellence in Bedford and León are intended to provide integrated formulation, process and analytical support across small molecules, biologics and high-potent compounds in presentations including vials, prefilled syringes and cartridges.
This co-location of development capability with GMP sterile manufacturing is significant because it helps streamline technology transfer, reduce development risk and shorten timelines. It is also increasingly representative of how leading CDMOs are thinking about investment: not as isolated bricks-and-mortar projects, but as linked scientific and manufacturing infrastructure intended to carry molecules more smoothly from early development into commercial supply.
The León, Spain facility is another example, with investment in syringe and cartridge filling alongside biologics development capability. Taken together, these projects illustrate how CDMOs are aligning capital allocation with the realities of today’s pipelines, where biologics, complex small molecules and potent therapies demand both specialized equipment and deeper technical integration.
Investing in drug-device combination infrastructure
Advanced drug-device combinations are another major focal point for investment, particularly as more biologics and complex injectables move into ready-to-use and ready-to-administer formats for self-injection. PCI has announced investments exceeding USD 365 million in infrastructure dedicated to the clinical- and commercial-scale assembly, testing and packaging of drug-device combination products, especially injectable delivery systems such as prefilled syringes, pens and autoinjectors. These commitments span North America and Europe and are intended to provide scalable support from lower-volume clinical work through commercial launch.
Within that programme, Rockford, Dublin and Dundalk serve as concrete examples of how capacity is being built around combination-product demand. But the broader industry implication is that these investments are no longer just about throughput. They are about flexibility across formats, alignment with evolving regulatory expectations around device-drug integration, and the ability to support clients as products move from vial-based presentation into device-based formats better suited to patient use.
That is why capital allocation decisions across the sector are increasingly shaped by multi-format capability, advanced inspection, packaging integration and cold-chain connectivity, rather than by filling capacity alone. In that respect, PCI’s expansion strategy is illustrative of a broader change in the way CDMOs are building for injectable and combination-product demand.
Building an integrated, resilient network
A final pillar of modern CDMO investment strategy is the creation of integrated, globally distributed networks that can manage the full lifespan of advanced drug delivery and drug-device combination products. Like several other global CDMOs, PCI has invested not only in manufacturing, but also in the storage, distribution and digital capabilities needed to support clinical supply, launch and commercial operations across regions.
Recent PCI investments therefore extend beyond production assets to include expanded ambient, refrigerated and frozen storage and distribution infrastructure, alongside digital supply-chain tools intended to improve collaboration, order management and operational visibility. For sponsors, these investments are increasingly as important as physical manufacturing capacity, because they enable faster decision-making and smoother execution across complex global supply chains.
Crucially, the investments in Bedford, León, San Diego, Rockford, Dublin and Dundalk are designed to function as part of a coordinated network rather than as isolated sites. That reflects a broader shift in CDMO investment logic: the objective is no longer simply to add capacity, but to build resilient networks that combine co-located development and manufacturing, regional optionality and digital connectivity to help programmes move more reliably from clinic to market.
Lessons for CDMO investment playbooks
Taken together, the market data and PCI’s recent investment programme highlight several principles that are increasingly shaping investment strategies across the sector. First, capital needs to follow therapeutic and format trends, particularly biologics, potent oncology agents and advanced injectable delivery systems, rather than legacy volume patterns. Second, integrating pharmaceutical development with commercial-ready sterile manufacturing and device assembly is becoming a differentiator because it shortens timelines, reduces technology-transfer risk and supports better lifecycle planning.
Third, geographic diversification and network design now underpin supply-chain resilience and sponsor confidence. Building capabilities on both sides of the Atlantic reflects a wider market preference for regional options, redundancy and flexibility in supply strategy. Finally, investments in digital platforms, analytical sophistication and high-potency containment are essential complements to physical expansion, ensuring that capacity is not only available but also controllable, transparent and suited to tomorrow’s molecules.
As complex injectables, biologics and combination products continue to reshape the therapeutic landscape, the CDMOs that succeed will be those that combine long-range, data-informed investment strategies with a clear view of where scientific innovation and patient needs are heading. For sponsors and their partners, that alignment between capital allocation, technical capability and supply-chain design will be central to turning promising molecules into reliable, globally available therapies over the decade ahead.